ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS

BACKGROUND: WHO grade II/III gliomas frequently harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in intratumoral accumulation of oncometabolite D-2-hydroxyglutarate (D-2-HG) and subsequent clonal expansion. DS-1001b is an oral selective inhibitor of mutant IDH1 R132X that was designed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Arakawa, Yoshiki, Mineharu, Yohei, Wakabayashi, Toshihiko, Natsume, Atsushi, Miyakita, Yasuji, Narita, Yoshitaka, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Hata, Nobuhiro, Muragaki, Yoshihiro, Nishikawa, Ryo, Shinojima, Naoki, Kumabe, Toshihiro, Saito, Ryuta, Ito, Kazumi, Tachibana, Masaya, Kakurai, Yasuyuki, Yamaguchi, Tomoyuki, Nishijima, Soichiro, Tsubouchi, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213087/
http://dx.doi.org/10.1093/noajnl/vdz039.063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213087/
http://dx.doi.org/10.1093/noajnl/vdz039.063

Ejemplares similares